Kopran Limited · NSE:KOPRAN
Kopran — H1 FY2023-24 Earnings Presentation
21 slides from Kopran's earnings presentation, 2023
Slide 1: One Direction, Endless Opportunities – Corporate Presentation Q2 and H1 2023-24
ONE DIRECTION, ENDLESS OPPORTUNITIES. CORPORATE PRESENTATION Q2 and H1 2023-24 KOPRAN LIMITED 1
Slide 2: Safe Harbour Statement
SAFE HARBOUR STATEMENT This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o
Slide 3: Kopran Limited: A Global Pharmaceutical Company
KOPRAN LIMITED A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International Quality 50+ Formulations and Active Pharmaceutical Ingredients (APIs) globally Nations - Export Reach State-of-the-art manufacturing facilities and products with various accredit
Slide 4: Business Overview API
BUSINESS OVERVIEW API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENTS Development, manufacturing and Anti-hypertensive sale of diverse APIs and Advanced Atenolol Macrolides Intermediates Cephalosporins - Non-Sterile & Sterile Neuromodulator One of the leaders in Atenolol Macroli
Slide 5: Business Overview Formulations
BUSINESS OVERVIEW FORMULATIONS FORMULATIONS VERTICAL PRODUCT SEGMENTS Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs Catering 100% export markets of both Regulated and Non-Regulated markets Manufacturers of more tha
Slide 6: Driving Sustainable Growth: Strategic Imperatives
DRIVING SUSTAINABLE GROWTH: STRATEGIC IMPERATIVES o Focus on R&D to develop niche, o Development of intermediates for high-value/high-volume APIs and APIs intermediates o Reducing dependence on China to o Capacity expansion move towards self sufficiency o Compliance with Global Regulatory COST o Opt
Slide 7: Driving Sustainable Growth: Regulatory Compliance
DRIVING SUSTAINABLE GROWTH REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards of manufacturing and quality at its all plants FORMULATIONS ACCREDITATIONS API ACCREDITATIONS Approved by 15 countries including MHRA (U
Slide 8: Operational Performance
OPERATIONAL PERFORMANCE
Slide 9: APIs Segment-wise Revenue Mix
OPERATIONAL HIGHLIGHTS APIs SEGMENT-WISE REVENUE MIX Q2 FY 2023-24 (₹ LAKHS) H1 FY 2023-24 (₹ LAKHS) Anti- Diabetic Anti- Diabetic 44.20 42.37 75.86 75.88 116.83 59.40 Anti- Infective 468.30 Anti- Infective 288.35 1,821.15 153.41 Antibiotic-Urological 1,256.49 Antibiotic-Urological Anti-Hypertensive
Slide 10: APIs Market-wise Revenue Mix
OPERATIONAL HIGHLIGHTS APIs MARKET-WISE REVENUE MIX Q2 FY 2023-24 (₹ LAKHS) H1 FY 2022-23 (₹ LAKHS) 3,589.61 6,617.26 Export Sales Export Sales Local Sales Local Sales 4,800.18 9,113.11 Total ₹ 8,389 Lakhs Total ₹ 15,730 Lakhs Note: Excluding solvent and scrap sales and includes API consumed for pro
Slide 11: Formulations Region-wise Sales Break-up
OPERATIONAL HIGHLIGHTS Formulations REGION-WISE SALES BREAK-UP Q2 FY 2023-24 (₹ LAKHS) H1 FY 2023-24 (₹ LAKHS) Africa Africa 891.14 488.59 Canada Canada 796.56 1,239.80 67.54 2,054.86 89.93 Latem Latem 3,699.54 South Africa South Africa Southeast Asia Southeast Asia UK 12.69 UK 12.69 Middle East and
Slide 12: Formulations Product-wise Revenue Mix
OPERATIONAL HIGHLIGHTS Formulations PRODUCT-WISE REVENUE MIX Q2 FY 2023-24 (₹ LAKHS) H1 FY 2023-24 (₹ LAKHS) 3,115.55 5,089.72 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 3,791.60 6,138.91 Total ₹ 6,907 Lakhs Total ₹ 11,228 Lakhs Note: Excluding Scrap Sales 12
Slide 13: Financial Performance
‘ a 7 % WwW 892 ae FINANCIAL PERFORMANCE
Slide 14: Financial Highlights: Consolidated Summary
FINANCIAL HIGHLIGHTS Consolidated PARTICULARS Q2 FY 2023-24 Q1 FY 2023-24 Summary Revenue from Operations 15,259 11,700 o Revenue from Operations increased by 30% to ₹ 15,259 Lakhs in EBITDA 2,283 631 Q2 FY 2023-24 as compared to ₹ 11,700 Lakhs in the previous quarter as the raw material and API pri
Slide 15: Financial Highlights Half-Yearly Snapshot
FINANCIAL HIGHLIGHTS HALF-YEARLY SNAPSHOT 50,980 55,405 48,813 36,013 27,211 SALES/OTHER INCOME (₹ LAKHS) 2019-20 2020-21 2021-22 2022-23 H1 2023- 8,739 8,178 24 4,696 4,672 EBITDA * 2,914 (₹ LAKHS) 891 2019-20 2020-21 2021-22 2022-23 H1 2023- 24 624 608 512 377 FINANCE COSTS (₹ LAKHS) 2019-20 2020-
Slide 16: Financial Highlights: Building Shareholder Value Year on Year
FINANCIAL HIGHLIGHTS BUILDING SHAREHOLDER VALUE YEAR ON YEAR RoE (%) RoCE (%) 28.3 22.4 14.5 25.3 20.1 7.9 11.8 4.5 EBITDA & EBITDA Margin 6.3 Total Debt/Equity (₹ Lakhs, %) 3.8 (X) 2019-20 2020-21 2021-22 2022-23 H1 18.30 2023-24 16.62 Return on Networth/Equity 14.95 13.06 Return on Capital Employe
Slide 17: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS PARTICULARS H1 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Revenue from Operations 26,959 55,098 47,752 49,181 35,949 Equity Share Capital 4,821 4,821 4,821 4,325 4,324 Other Equity 39,322 39,104 37,796 20,177 14,643 Net Worth 44,143 43,925 42,617 24,503
Slide 18: Governance Board of Directors
GOVERNANCE BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDE
Slide 19: Ownership Structure
OWNERSHIP STRUCTURE KOPRAN LIMITED SHAREHOLDING PATTERN (%) 2.41 Promoters Non-Institutions 43.78 Financial Institutions KOPRAN KOPRAN RESEARCH KOPRAN (H.K.) LIFESCIENCES LABORATORIES LIMITED LIMITED LIMITED* 53.82 KOPRAN (UK) LIMITED 19
Slide 20: Contact Us
CONTACT US ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Developmen
Slide 21: Thank You
THANK YOU